Kennislacunes

Met de huidige onderzoeksvraag is gekeken naar wat beter is: targeted therapie of chemotherapie/ best supportive care. Er komen steeds meer studies waarbij of twee targeted therapien met elkaar vergeleken worden, of bij de meest zeldzame mutaties nieuwe single arm studies worden gepubliceerd.

 

Derhalve een iets aangepaste PICO ten opzichte van de huidige: Which targeted therapy is preferred (first generation / next generation, or combinations with TKI) in patients with NSCLC and a targetable driver mutation?

 

P (population) patients with non–small-cell lung cancer stage IIIB/IV and a targetable driver mutation/aberration (ALK, ROS1, BRAF, RET, MET, HER2, NTRK or NRG);

I (intervention) targeted therapy (tyrosine kinase inhibitor, crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, entrectinib, dabrafenib, trametinib, vemurafenib, cabozantinib, vandetanib, sunitinib, sorafenib, lenvatinib, nintedanib, ponatinib, regorafenib, capmatinib, afatinib);

C (comparison) targeted therapy (tyrosine kinase inhibitor, crizotinib, ceritinib, alectinib, brigatinib, lorlatinib, entrectinib, dabrafenib, trametinib, vemurafenib, cabozantinib, vandetanib, sunitinib, sorafenib, lenvatinib, nintedanib, ponatinib, regorafenib, capmatinib, afatinib);

O (outcome) overall survival, progression free survival, objective response rate, quality of life and adverse events.